Skip to main content
NextGen Biomed Ltd. logo

NextGen Biomed Ltd. — Investor Relations & Filings

Ticker · NXGN ISIN · IL0010839301 TA Professional, scientific and technical activities
Open in API
Filings indexed 8 across all filing types
Latest filing 2026-01-18 Delisting Announcement
Country IL Israel
Listing TA NXGN

About NextGen Biomed Ltd.

https://www.nextgen-biomed.com/

NextGen Biomed Ltd. is a research and development company operating in the biotechnology and medical device sectors. The company specializes in developing novel therapeutic delivery systems, with a primary focus on its EyePen product, a smart and modular device for injections. Its technology platform centers on creating pain-free auto-injectors and lancet devices that utilize a proprietary cooling technology to alleviate discomfort. The company's broader activities aim to advance the fields of biologics, vaccines, and novel therapeutic approaches through its innovative delivery solutions.

Recent filings

Filing Released Lang Actions
The company is a "shell company", its shares will be transferred to the maintenance list on January 20, 2026 ; Sector Change
Delisting Announcement Classification · 1% confidence The document is a formal notice from the Tel Aviv Stock Exchange (TASE) regarding the status change of NextGen Biomed Ltd to a 'shell company' and its subsequent transfer to the maintenance list. This is a regulatory announcement concerning the listing status of the company's securities, which fits the definition of a regulatory filing or announcement regarding exchange rules, rather than a delisting itself, as it describes a transfer to a maintenance list.
2026-01-18 English
Scentech Medical presentation
Investor Presentation Classification · 1% confidence The document is a slide deck titled 'Scentech Medical Shareholder Update'. It provides an overview of the company's technology (VOC-based diagnostics), development progress, clinical problem statements, and strategic transactions. It is clearly designed for investors to understand the company's business model, roadmap, and current status. This aligns perfectly with the definition of an Investor Presentation (IP).
2026-01-14 English
Scentech Medical presentation
AGM Information Classification · 1% confidence The document is a short regulatory filing (T121) from the Israel Securities Authority (MAGNA system) announcing the publication of an investor presentation ('מצגת לשוק ההון') for a subsidiary. Because the document is short, serves as a cover notice for an attached file, and explicitly states that the presentation is attached, it falls under the 'Report Publication Announcement' category according to the 'Menu vs Meal' rule.
2026-01-14 Russian
Trading in the company's shares will be renewed on January 6 , 2026
Regulatory Filings Classification · 1% confidence The document is a short notice from the Tel Aviv Stock Exchange (TASE) regarding the resumption of trading for NextGen Biomed Ltd following the publication of overdue financial statements. It is a regulatory announcement concerning market operations and trading status, which does not fit into specific categories like earnings releases or financial reports. Therefore, it is classified as a general regulatory filing.
2026-01-04 English
Trading in the company's shares (ISIN IL0010839301) will be renewed on Tuesday, July 2, 2024, on the main list
Regulatory Filings
2024-06-30 Hebrew (modern)
Trading in the company's shares has been suspended since the company has not yet submitted its financial reports
Regulatory Filings
2024-05-01 Hebrew (modern)

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.